Sugi Predict

Sugi Predict / Compounds / Pachypodol

Pachypodol

Pachypodol

SCHEMBL39280

COc1cc(O)c2c(=O)c(OC)c(-c3ccc(O)c(OC)c3)oc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 5/20 1.00
▸ ABCB1 P08183 3/20 0.87
▸ ABCC1 P33527 3/20 0.87
▸ PLG P00747 1/20 0.82
▸ NOX4 Q9NPH5 1/20 0.82
▸ TUBB4A P04350 1/20 0.69
▸ TUBB P07437 1/20 0.69
▸ TUBA3C P0DPH7 1/20 0.69
▸ TUBA1B P68363 1/20 0.69
▸ TUBA4A P68366 1/20 0.69
▸ TUBB4B P68371 1/20 0.69
▸ TUBB3 Q13509 1/20 0.69
▸ TUBB2A Q13885 1/20 0.69
▸ TUBB8 Q3ZCM7 1/20 0.69
▸ TUBA3E Q6PEY2 1/20 0.69
▸ TUBA1A Q71U36 1/20 0.69
▸ TUBA1C Q9BQE3 1/20 0.69
▸ TUBB6 Q9BUF5 1/20 0.69
▸ TUBB2B Q9BVA1 1/20 0.69
▸ TUBB1 Q9H4B7 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pachypodol SCHEMBL29929114 1.00 ABCG2 (1.00) ABCG2ABCB1ABCC1PLGNOX4
SCHEMBL4286969 0.93 ABCG2 (0.87) ABCG2ABCB1ABCC1PLGNOX4
Retusin SCHEMBL29496204 0.93 ABCG2 (1.00) ABCG2ABCB1ABCC1PLGNOX4
Retusin SCHEMBL1421755 0.93 ABCG2 (1.00) ABCG2ABCB1ABCC1PLGNOX4
Retusin SCHEMBL4279671 0.92 ABCG2 (0.98) ABCG2ABCB1ABCC1PLGNOX4
3,3'-O-Dimethylquercetin SCHEMBL1252850 0.92 ABCG2 (0.84) ABCG2ABCB1ABCC1PLGNOX4
3,3'-O-Dimethylquercetin SCHEMBL29443769 0.92 ABCG2 (0.84) ABCG2ABCB1ABCC1PLGNOX4
SCHEMBL11276654 0.91 ABCG2 (0.83) ABCG2ABCB1ABCC1PLGNOX4
SCHEMBL17773721 0.91 ABCG2 (0.83) ABCG2ABCB1ABCC1PLGNOX4
3,3'-O-Dimethylquercetin SCHEMBL25243901 0.91 ABCG2 (0.83) ABCG2ABCB1ABCC1PLGNOX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3346842-B1 STABLE INOCULANT COMPOSITIONS AND METHODS FOR PRODUCING SAME NOVONESIS PLANT BIOSOLUTIONS AS (DK) 2026-03-25 — — EP claimed
EP-4698662-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2026-02-25 — — EP claimed
US-12514929-B2 Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-01-06 — — US claimed
WO-2025235852-A1 FLAVONOID COMPOSITIONS AND METHODS OF USE SYNGENTA CROP PROTECTION AG (CH) 2025-11-13 — — WO claimed
US-12458049-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2025-11-04 — — US claimed
WO-2024220449-A9 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES AskBio Inc. (US) 2025-04-03 — — WO claimed
WO-2025038482-A2 USE OF FISETIN FOR REDUCING THE INCIDENCE OF ATRIAL FIBRILLATION RHODE ISLAND HOSPITAL (US) 2025-02-20 — — WO claimed
WO-2024220449-A2 REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) 2024-10-24 — — WO claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US claimed
US-20240188613-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF FIRMENICH INCORPORATED 2024-06-13 — — US claimed
WO-2009073437-A1 POLYSACCHARIDE GEL FORMULATION ALLERGAN, INC. (US) 2009-06-11 — — WO claimed
US-20090143331-A1 POLYSACCHARIDE GEL FORMULATION HAVING INCREASED LONGEVITY ALLERGAN INDUSTRIE, SAS (FR) 2009-06-04 — — US claimed
US-20090098254-A1 Methods And Compositions For Improving Sensory And Shelf Life Characteristics Of Raw Meat Products TYSON FOODS, INC. 2009-04-16 — — US claimed
EP-0290442-A4 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS. CHEMEX PHARMACEUTICALS INC (US) 1990-07-03 — — EP claimed
EP-0290442-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-11-17 — — EP claimed
US-4774229-A ANTITUMOR AGENTS, SKIN DISORDERS, CANCER TREATMENT CHEMEX PHARMACEUTICALS, INC. (US) 1988-09-27 — — US claimed
WO-1988003805-A1 PHARMACOLOGICALLY ACTIVE COMPOUNDS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS CHEMEX PHARMACEUTICALS, INC. (US) 1988-06-02 — — WO claimed
WO-1987006833-A1 MODIFICATION OF PLANT EXTRACTS FROM ZYGOPHYLLACEAE CHEMEX PHARMACEUTICALS, INC. (US) 1987-11-19 — — WO claimed
US-4352792-A 3-Alkoxyflavone antiviral agents HOFFMANN-LA ROCHE INC. (US) 1982-10-05 — — US claimed
EP-0019081-A1 Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1980-11-26 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458049-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 ABCG2 73/4885ABCB1 1442/4885ABCC1 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.